Volume 9, Issue 3 pp. 242-253
Main Paper

Assessing consistent treatment effect in a multi-regional clinical trial: a systematic review

Joshua Chen

Corresponding Author

Joshua Chen

Merck Research Labs, UG1CD-44, North Wales, PA, USA

Merck Research Labs, PO Box 1000, UG1CD-44, North Wales, PA, USASearch for more papers by this author
Hui Quan

Hui Quan

Sanofi-Aventis, Biostatistics and Programming, Bridgewater, NJ, USA

Search for more papers by this author
Bruce Binkowitz

Bruce Binkowitz

Merck Research Labs, UG1CD-44, North Wales, PA, USA

Search for more papers by this author
S. Peter Ouyang

S. Peter Ouyang

Celgene, Summit, NJ, USA

Search for more papers by this author
Yoko Tanaka

Yoko Tanaka

Eli Lilly, Indiapolis, IN, USA

Search for more papers by this author
Gang Li

Gang Li

Johnson & Johnson, Raritan, NJ, USA

Search for more papers by this author
Shailendra Menjoge

Shailendra Menjoge

Boehringer Ingelheim, Ridgefield, CT, USA

Search for more papers by this author
Ekopimo Ibia

Ekopimo Ibia

Merck Research Labs, UG1CD-44, North Wales, PA, USA

Search for more papers by this author
for the Consistency Workstream of the PhRMA MRCT Key Issue Team

for the Consistency Workstream of the PhRMA MRCT Key Issue Team

Consistency Workstream of the PhRMA MRCT Key Issue Team: Hui Quan, Joshua Chen, Yoko Tanaka, Gang Li, Paul Gallo, Peter Ouyang, Xiaolong Luo, Shailendra Menjoge, Steven Talerico, Kimitoshi Ikeda, Bruce Binkowitz, Ekopimo Ibia.

Search for more papers by this author
First published: 14 May 2010
Citations: 52

This article is published in Pharmaceutical Statistics as a special issue on Multi-regional Clinical Trials–What are the challenges?, edited by Sue Jane Wang, Office of Biostatistics, Office of Translational Sciences, CDER, U.S. Food and Drug Administration, MD, USA

Abstract

A key issue in multi-regional clinical trials (MRCTs) is how to assess the consistency of treatment effect across regions, although there is no a priori reason to believe that the treatment effect should vary across the regions. In this article, we define the research question as an assessment of overall consistency across all regions for which all regions are considered equally important. This is different from the region/country-specific analyses (e.g. US vs Non-US), which are frequently requested by local regulatory agencies and usually performed for multiple agencies. We provide a systematic review of methods that may potentially be used for assessing consistency across regions, including commonly used quantitative/qualitative interaction tests, Japanese Pharmaceutical Medical Device Agency (PMDA) Methods 1 & 2, and those proposed for different purposes (e.g. bridging studies, meta-analysis, and vaccine lot consistency, among others). These methods are classified into three groups: global methods, multivariate quantitative methods, and multivariate qualitative methods. A case study is used to illustrate these methods. We also provide recommendations on how to choose appropriate methods and incorporate them in the study design. Copyright © 2010 John Wiley & Sons, Ltd.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.